We are live on ! Find out more
BCM

BML Capital Management Portfolio holdings

AUM $156M
1-Year Est. Return 129.82%
This Fund
S&P 500
This Quarter Est. Return
+14.88%
1 Year Est. Return
+129.82%
3 Year Est. Return
+394.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$132M
AUM Growth
+$8.62M
Cap. Flow
-$414K
Cap. Flow %
-0.31%
Top 10 Hldgs %
86.67%
Holding
29
New
2
Increased
10
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
ALMS
Alumis Inc
ALMS
+$5.48M
2
TIL icon
Instil Bio
TIL
+$2.47M
3
PMVP icon
PMV Pharmaceuticals
PMVP
+$1.23M
4
KZR
Kezar Life Sciences
KZR
+$973K
5
ADVM
Adverum Biotechnologies
ADVM
+$882K

Top Sells

Rank Stock Value
1
ANTX icon
AN2 Therapeutics
ANTX
+$7.82M
2
WHWK
Whitehawk Therapeutics
WHWK
+$3.36M
3
SAGE
Sage Therapeutics
SAGE
+$1.07M
4
CNTB
Connect Biopharma Holdings
CNTB
+$217K
5
NXTC icon
NextCure
NXTC
+$131K

Sector Composition

Rank Sector Weight
1 Healthcare 97.79%
2 Technology 0.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVIR icon
1
Atea Pharmaceuticals
AVIR
$377M
$27.4M 20.73%
7,609,812
– –
THRD
2
DELISTED
Third Harmonic Bio
THRD
$20.8M 15.71%
3,824,417
– –
ACRS icon
3
Aclaris Therapeutics
ACRS
$749M
$20.2M 15.31%
14,250,000
– –
TIL icon
4
Instil Bio
TIL
$50.9M
$11.1M 8.43%
534,899
+118,179
+28% +$2.47M
EPIX
5
DELISTED
ESSA Pharma
EPIX
$7.18M 5.43%
4,221,546
– –
ORMP icon
6
Oramed Pharmaceuticals
ORMP
$166M
$6.94M 5.25%
3,083,253
+62,505
+2% +$138K
ADVM
7
DELISTED
Adverum Biotechnologies
ADVM
$6.57M 4.97%
3,057,526
+315,209
+11% +$882K
IMA
8
ImageneBio Inc
IMA
$61.5M
$5.4M 4.09%
335,842
+26,608
+9% +$391K
PMVP icon
9
PMV Pharmaceuticals
PMVP
$69.3M
$5.3M 4.01%
5,000,000
+1,252,388
+33% +$1.23M
ALMS
10
Alumis Inc
ALMS
$3.47B
$3.63M 2.75%
1,210,415
+1,160,788
+2,339% +$5.48M
KZR
11
DELISTED
Kezar Life Sciences
KZR
$2.91M 2.2%
635,183
+227,045
+56% +$973K
LVTX
12
DELISTED
LAVA Therapeutics
LVTX
$2.6M 1.97%
1,970,610
+10,000
+0.5% +$12.7K
MIST icon
13
Milestone Pharmaceuticals
MIST
$154M
$2.2M 1.67%
1,136,091
– –
ELEV
14
DELISTED
Elevation Oncology
ELEV
$2.16M 1.64%
5,890,434
-500
-0% -$167
CNTB
15
Connect Biopharma Holdings
CNTB
$147M
$1.79M 1.35%
1,821,558
-271,674
-13% -$217K
TSLA icon
16
PUT
Tesla
TSLA
$1.47T
$1.65M 1.25%
+200
New +$60.3K
ASTC icon
17
Astrotech Corp
ASTC
$15.1M
$1.27M 0.96%
220,410
– –
LONA
18
LeonaBio Inc
LONA
$73.4M
$976K 0.74%
323,067
+3,000
+0.9% +$8.49K
LSTA icon
19
Lisata Therapeutics
LSTA
$31.9M
$608K 0.46%
209,814
-7,039
-3% -$16.9K
CRVS icon
20
Corvus Pharmaceuticals
CRVS
$1.2B
$475K 0.36%
+118,766
New +$432K
TSBX
21
DELISTED
Turnstone Biologics
TSBX
$396K 0.3%
1,103,386
– –
VTGN icon
22
VistaGen Therapeutics
VTGN
$9.85M
$300K 0.23%
150,000
– –
HLVX
23
DELISTED
HilleVax
HLVX
$183K 0.14%
91,913
+71,153
+343% +$130K
VRCA icon
24
Verrica Pharmaceuticals
VRCA
$95.5M
$92.6K 0.07%
17,465
– –
ANTX icon
25
AN2 Therapeutics
ANTX
$168M
– –
-5,749,432
Closed -$7.82M
1
2

Similar funds

AIS
Accredited Investor Services St. Cloud, Minnesota $156M AUM 21.61% 1-Year Est. Return
BWM
BNB Wealth Management Silver Spring, Maryland $156M AUM
TI
Truxt Investmentos Rio De Janeiro, Brazil $156M AUM
CFG
Cornerstone Financial Group Omaha, Nebraska $156M AUM 12% 1-Year Est. Return
IWA
Invera Wealth Advisors Bend, Oregon $156M AUM 22.76% 1-Year Est. Return
PFO
Pioneer Family Office North Miami Beach, Florida $156M AUM
HCWM
Hidden Cove Wealth Management Bainbridge Island, Washington $156M AUM 16.51% 1-Year Est. Return
BCM
Bluefin Capital Management New York $156M AUM 18.47% 1-Year Est. Return

BML Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, BML Capital Management held 29 positions worth $132M, up 7% from $124M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

BML Capital Management's Q2 2025 filing shows 2 new, 10 increased, 3 reduced and 5 closed positions. Its largest new stake was Corvus Pharmaceuticals: 118,766 shares worth $475K. The largest sale was AN2 Therapeutics, an estimated $7.82M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Technology.

  • BML Capital Management's largest Q2 2025 buy was Corvus Pharmaceuticals: 118,766 shares worth $475K.
  • BML Capital Management added most to Alumis Inc in Q2 2025, an estimated $5.48M increase.
  • BML Capital Management's biggest Q2 2025 reduction was Connect Biopharma Holdings, cutting an estimated $217K.
  • BML Capital Management fully exited AN2 Therapeutics in Q2 2025, selling an estimated $7.82M.
  • BML Capital Management's ten largest holdings make up 87% of its $132M portfolio in Q2 2025.
  • BML Capital Management opened 2 new positions and closed 5 in Q2 2025.
  • BML Capital Management's portfolio value rose 7% quarter-over-quarter to $132M.

Based on BML Capital Management's 13F filing for Q2 2025, filed 11 Aug 2025.